Emerging data from various ongoing phase II studies have indicated that the addition of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1(PD-L1) inhibitors alone or in combination with chemotherapy before surgery may significantly improve the survival of resectable NSCLC (1–5). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.